Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd (CANF)

Can-Fite Biopharma Ltd (CANF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,759
  • Shares Outstanding, K 17,192
  • Annual Sales, $ 760 K
  • Annual Income, $ -14,440 K
  • 60-Month Beta 1.95
  • Price/Sales 47.09
  • Price/Cash Flow N/A
  • Price/Book 5.55
Trade CANF with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.19
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +76.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.04 +6.86%
on 04/19/21
2.82 -22.70%
on 03/22/21
-0.64 (-22.70%)
since 03/19/21
3-Month
1.69 +28.99%
on 03/05/21
4.39 -50.34%
on 03/16/21
+0.23 (+11.79%)
since 01/20/21
52-Week
1.51 +44.37%
on 09/04/20
4.39 -50.34%
on 03/16/21
+0.35 (+19.13%)
since 04/20/20

Most Recent Stories

More News
Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today...

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)
New Strong Sell Stocks for April 19th

PAC, CANF, GOL, HRTH, and INLX have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2021

PAC : 104.07 (-1.39%)
GOL : 7.94 (-5.02%)
CANF : 2.18 (+4.81%)
INLX : 4.2500 (-10.53%)
HRTH : 4.1300 (+3.25%)
Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today...

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)
Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced...

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)
Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

--"2020 was a pivotal year for Can-Fite as we demonstrated a robust clinical proof of concept for both Piclidenoson and Namodenoson," stated Can-Fite CEO Dr. Pnina Fishman

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

PCRX : 62.65 (-1.35%)
CANF : 2.18 (+4.81%)
OPHLF : 25.0500 (unch)
SLNO : 1.1000 (-6.78%)
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report(R)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)
Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, OCG, SINO, BAC, and CANF.

CANF : 2.18 (+4.81%)
NEOS : 1.1500 (-2.54%)
OCG : 5.05 (+4.12%)
SINO : 4.21 (-3.66%)
BAC : 38.08 (-2.78%)
Thinking about buying stock in Can Fite Biopharma, Aytu Bioscience, Hall of Fame Resort & Entertainment, Brickell Biotech, or Infinity Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, AYTU, HOFV, BBI, and INFI.

CANF : 2.18 (+4.81%)
BBI : 0.8220 (-2.15%)
HOFV : 3.11 (+1.30%)
INFI : 2.78 (-2.46%)
Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced...

CANF : 2.18 (+4.81%)
CFBI : 10.08 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.30
1st Resistance Point 2.24
Last Price 2.18
1st Support Level 2.09
2nd Support Level 2.00
3rd Support Level 1.94

See More

52-Week High 4.39
Fibonacci 61.8% 3.29
Fibonacci 50% 2.95
Fibonacci 38.2% 2.61
Last Price 2.18
52-Week Low 1.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar